Novartis v. MSN Pharmaceuticals: Federal Circuit Affirms Entresto® Patents
Novartis AG secured a Federal Circuit affirmance of three patents covering its blockbuster heart failure drug Entresto® (sacubitril/valsartan) against MSN Pharmaceuticals and affiliated entities. The appeal resolved in 113 days, leaving all three asserted patents intact and MSN’s generic entry path blocked.
Federal Circuit closes MSN’s generic Entresto challenge in 113 days
Novartis AG, holder of three US patents covering its sacubitril/valsartan heart failure tablets marketed as Entresto®, brought this infringement action against MSN Pharmaceuticals Inc., MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd., and Gerbera Therapeutics Inc. The asserted patents — US8101659B2, US11058667B2, and US11096918B2 — protect the compound, formulation, and related methods underlying Entresto® at its three approved dosage strengths: 24/26 mg, 49/51 mg, and 97/103 mg.
The Federal Circuit issued an affirmance on 4 December 2024, approximately 113 days after the appeal was filed on 13 August 2024. An affirmance at this level means the appellate court identified no reversible legal error in the lower tribunal’s findings; the district court ruling protecting Novartis’s patents remains fully operative. The basis of termination is recorded as ‘Appeal Dismissed,’ consistent with an entry of affirmance that terminates the appellate proceeding without remand.
A 113-day resolution is notably swift for a multi-patent pharmaceutical Federal Circuit appeal, suggesting the court may have found the legal questions sufficiently settled on the record to resolve without extended briefing or oral argument. The public record does not disclose whether a settlement accompanied the affirmance, nor does it detail any licensing terms. What remains clear is that MSN’s pathway to a generic sacubitril/valsartan product in the US faces a substantially higher barrier following this outcome.
Filing to Appeal Dismissed in 113 days
113 days — faster than typical Federal Circuit pharma appeals, which often run 18–24 months
Federal Circuit affirms: what the ruling means for both parties
Affirmance means the lower decision stands — no reversible error found
When the Federal Circuit affirms, it concludes that the lower court committed no reversible legal error in its analysis of validity, infringement, or both. All three Novartis patents — US8101659B2, US11058667B2, and US11096918B2 — retain the full force of the prior ruling. The appellate court does not issue a new merits decision; it endorses the existing one, which now carries additional precedential weight having survived appeal.
No reversible error foundNovartis’s Entresto® IP portfolio emerges stronger and harder to challenge
For Novartis, affirmance is the optimal appellate result. All three asserted sacubitril/valsartan patents survive MSN’s challenge with their enforceability intact. A patent that has withstood both district court scrutiny and Federal Circuit review is typically treated as more robust in any subsequent licensing negotiation or parallel ANDA dispute. This ruling also reinforces Novartis’s ability to enforce the same patents against other generic filers targeting Entresto®.
Patents survive, enforceability strengthenedMSN’s appellate options are exhausted at the Federal Circuit level
MSN Pharmaceuticals and its affiliates — including Gerbera Therapeutics — have exhausted their Federal Circuit appellate avenue. Further challenge would require a petition for certiorari to the US Supreme Court, an avenue that is rarely granted in patent cases absent a circuit split or significant constitutional question. Inter partes review petitions at the USPTO represent a separate, parallel channel that remains theoretically available, though the affirmed record raises the evidentiary bar considerably.
Federal Circuit avenue exhaustedGeneric sacubitril/valsartan entry faces a reinforced patent barrier in the US
Entresto® generated multi-billion dollar revenues for Novartis in recent years; blocking generic entry extends that exclusivity window. Any other generic manufacturer with a pending ANDA for sacubitril/valsartan tablets must now contend with three patents that have survived both district and appellate review. This affirmance signals to the sector that Novartis’s layered patent strategy — compound, formulation, and method claims — is durable, raising the cost and risk of any future generic or biosimilar challenge in this therapeutic space.
Extended US market exclusivityFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novartis, AG | Company | Global pharmaceutical innovator — holder of US8101659B2, US11058667B2, and US11096918B2 (Entresto®)Search in Eureka ↗ |
| Defendant | Msn Pharmaceuticals, Inc. | Company | Generic pharmaceutical manufacturer and affiliated entities seeking to market sacubitril/valsartan tabletsSearch in Eureka ↗ |
| Co-Defendant | GERBERA THERAPEUTICS INC. | Company | Search in Eureka ↗ |
| Co-Defendant | MSN Laboratories Private, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | MSN Life Sciences Private, Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Christopher Earl Loh | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Deanne Maynard | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Jared Levi Stringham | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Joel F. Wacks | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Rebecca Emily Weires | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Seth W. Lloyd | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff law firm | Morrison & Foerster LLP | Law Firm | Representing Novartis, AGSearch in Eureka ↗ |
| Plaintiff law firm | Venable LLP | Law Firm | Representing Novartis, AGSearch in Eureka ↗ |
| Defendant counsel | Richard Charles Weinblatt | Attorney | Counsel for Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Richard Juang | Attorney | Counsel for Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Ronald M. Daignault | Attorney | Counsel for Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Daignault Iyer LLP | Law Firm | Representing Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Stamoulis & Weinblatt LLC | Law Firm | Representing Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘AFFIRMED’ — is unambiguous: the appellate panel found no reversible error in the lower court’s disposition of the infringement claims covering Novartis’s Entresto® patents. At the Federal Circuit, affirmance is evaluated against substantial evidence (for factual findings) and de novo (for legal conclusions such as claim construction). The terse order suggests the panel was not persuaded that MSN raised a meritorious legal or factual challenge warranting reversal or remand. Both the validity and infringement findings, as established below, now carry the added durability of appellate endorsement.
US8101659B2, US11058667B2 & US11096918B2 — Sacubitril/Valsartan Heart Failure Tablets
The three patents-in-suit protect Novartis’s Entresto® (sacubitril/valsartan) across staggered layers of IP protection. US8101659B2, filed on application US12/147570, covers the sacubitril/valsartan compound itself — the angiotensin receptor-neprilysin inhibitor (ARNI) combination that is pharmacologically central to Entresto®. US11058667B2 (application US15/572399) and US11096918B2 (application US16/579581) extend protection to formulation and method aspects, filed in the late 2010s and thus providing exclusivity well into the 2030s. Together, these patents cover the 24/26 mg, 49/51 mg, and 97/103 mg tablet strengths approved in the US.
Entresto® is one of the highest-revenue cardiovascular drugs globally, with annual sales exceeding several billion dollars. The layered patent architecture — compound, formulation, and method claims — is a deliberate strategy to extend commercial exclusivity beyond the base compound patent expiry. For generic manufacturers, invalidating or designing around all three patents simultaneously presents a substantial challenge, a difficulty reflected in the Federal Circuit’s affirmance. Any company active in the heart failure therapeutic space, or developing ARNI-class compounds, should treat these patents as high-priority monitoring assets.
Should you run an FTO against US8101659B2, US11058667B2, and US11096918B2?
Any pharmaceutical manufacturer, formulator, or API supplier working on angiotensin receptor-neprilysin inhibitor (ARNI) combinations, sacubitril-containing compounds, or valsartan co-formulations for heart failure indications should treat these three patents as mandatory FTO checkpoints. The Federal Circuit affirmance materially increases their enforceability risk profile. Even products with distinct dosage forms or modified release profiles may fall within the scope of the formulation and method claims in US11058667B2 and US11096918B2.
PatSnap Eureka’s FTO Search Agent can rapidly map the claim scope of all three Novartis patents, identify prior art that has not yet been cited in IPR proceedings, and surface related family members and continuation applications that may extend coverage further. For in-house IP teams at generic manufacturers or innovator competitors developing next-generation heart failure therapies, Eureka can generate a structured FTO report, flag prosecution history estoppel risks, and benchmark claim language against your specific compound or formulation profile — reducing the time from question to defensible legal position.
Run a freedom-to-operate analysis on US8101659B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA Patent Appeals at the Federal Circuit: Cardiovascular Drug Cases
Explore Federal Circuit appeals in pharmaceutical patent infringement cases involving ANDA challenges to branded cardiovascular and heart failure drugs, comparable to Novartis v. MSN.
What this case signals for the cardiovascular pharma IP landscape
The Federal Circuit’s swift affirmance reinforces Novartis’s multi-patent Entresto® fortress and raises the stakes for any future ANDA filer targeting sacubitril/valsartan.
Layered patent strategies survive: compound + formulation + method claims all upheld
Novartis asserted three patents covering distinct IP layers: the sacubitril/valsartan compound (US8101659B2), a later formulation patent (US11058667B2), and a further method/formulation patent (US11096918B2). The affirmance of all three suggests that courts are willing to uphold staggered patent portfolios protecting the same commercial product, provided each patent addresses a distinct inventive contribution. Competitors and IP strategists should note that challenging only one layer may be insufficient to clear the path to market.
Speed of resolution (113 days) suggests a procedurally streamlined Federal Circuit docket
A 113-day Federal Circuit appeal in a multi-patent pharmaceutical infringement case is well below the typical timeline. This pace is consistent with a summary affirmance procedure or an expedited briefing schedule, potentially indicating that the panel found the lower court record sufficient to decide without full argument. IP teams monitoring Federal Circuit appeal timelines in ANDA litigation should factor in the possibility of accelerated outcomes when the district record is well-developed.
Novartis v Msn — key questions answered
The Federal Circuit affirmed the lower court’s ruling in favour of Novartis AG on 4 December 2024. All three asserted patents — US8101659B2, US11058667B2, and US11096918B2 — covering Entresto® (sacubitril/valsartan) tablets were upheld. MSN Pharmaceuticals and its affiliates’ challenge was rejected without remand, and the appeal was terminated in 113 days.
In this litigation, Novartis asserted three US patents: US8101659B2 (application US12/147570, covering the sacubitril/valsartan compound), US11058667B2 (application US15/572399, formulation patent), and US11096918B2 (application US16/579581, further formulation and method patent). These cover Entresto® at 24/26 mg, 49/51 mg, and 97/103 mg dosage strengths. All three were affirmed by the Federal Circuit in Case No. 24-2212.
The defendants are MSN Pharmaceuticals Inc., MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd., and Gerbera Therapeutics Inc. This structure is typical of ANDA litigation where a US-based entity (here MSN Pharmaceuticals and Gerbera Therapeutics) holds the generic drug application while foreign affiliates (MSN Laboratories and MSN Life Sciences, both India-based) manufacture the active pharmaceutical ingredient or finished dosage form.
The affirmance means the district court’s infringement findings stand without modification. MSN and its affiliates cannot market their sacubitril/valsartan generic in the US without risking contempt. Other ANDA filers for Entresto® generics must now contend with three patents that have survived appellate review, substantially raising the cost and risk of any challenge. IPR petitions at the USPTO remain a separate route, but the affirmed litigation record strengthens Novartis’s position there too.
The appeal was filed on 13 August 2024 and decided on 4 December 2024 — a period of 113 days. This is notably faster than the typical Federal Circuit pharmaceutical patent appeal, which often takes 18–24 months to resolve. The speed of resolution may suggest a summary affirmance procedure or that the panel found the legal questions sufficiently settled on the record to decide without extended briefing or oral argument. The public record does not confirm the specific procedural mechanism used.
PatSnap Eureka searches patents and litigation data to answer instantly.